药品集中招标采购中“二次议价”的弊端及解决对策  

Drawbacks of "the Second Bargain" of Drug Centralized Bidding Procurement and the Solutions

作　　者：张莹[1] 陈玉文[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016

出　　处：《中国药事》2013年第3期255-257,共3页Chinese Pharmaceutical Affairs

摘　　要：目的为加强药品价格管理,进一步完善招标采购制度提供参考。方法采用文献研究法和逻辑推理法,对"二次议价"的现状、产生的原因和弊端进行分析,并提出相应对策。结果与结论 "二次议价"一方面助长了药品购销的不正之风,影响招标采购中药品价格的确定;另一方面会影响药品质量,造成部分品种短缺。经济利益驱使、处罚力度不足、监管不到位和部分药品中标价格不合理,是引起"二次议价"问题的主要原因。要通过加大处罚力度、加强监督、建立完善的政府补偿机制和确定科学合理的药品中标价格等方法,防止"二次议价"问题的出现。Objective To strengthen drug price management and provide reference for the standardization of centralized bidding procurement. Methods In order to put forward countermeasures, the current situation, reasons and drawbacks of ＂the second bargain＂ were analyzed based on literature research and logic reasoning. Results and Conclusion On the one hand,＂ the second bargain＂ could encourage unhealthy tendencies of drug trade and affect definiting drug price; on the other hand, it could influence the quality of drug and lead to the shortage of the types of drug. Reasons of ＂the second bargain＂ include light punishment, poor supervision and unreasonable bid price. To prevent ＂the second bargain＂, punishment should be strengthened, compensatory system should be completed, supervision should be strengthened, and drug bid price should be made reasonable.

关 键 词：“二次议价” 药品集中招标采购 商业贿赂 

分 类 号：R95[医药卫生—药学]